Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition and application thereof

A composition and medicine technology, applied in the field of medicine, can solve the problems of multiple organs, multi-function disorders, limited self-care ability, nervous system dysfunction, etc., and achieve the effects of enhancing the effect of dilating blood vessels, inhibiting platelet aggregation, and improving learning and memory.

Inactive Publication Date: 2011-07-20
HEILONGJIANG ZBD PHARMA
View PDF5 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Stroke is still the primary cause of disability in adults. About 1 / 2 of stroke patients will cause varying degrees of disability. Most patients have sequelae such as hemiplegia, dementia, limb twitching, slurred speech, and limited self-care ability. , which not only increases the pain of the patient, but also brings great difficulties to the family and society.
In particular, there are obvious differences between the mental state of stroke patients and normal people. They have poor adaptability to new environments, negative coping, and inability to effectively self-regulate. Bad mentality and malignant stimuli can cause nervous system dysfunction, resulting in multi-organ and multifunctional disorders. adversely affect the body

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition and application thereof
  • Pharmaceutical composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Extraction of components:

[0021] 1000 g of Panax notoginseng medicinal materials are crushed into coarse powder, 2.5 times the amount of 90% ethanol is added, and the mixture is heated to reflux for extraction, and concentrated under reduced pressure until it has no alcohol taste. Dilute with water to 0.25g (crude medicine) / ml, stand for 24 hours, and filter. The filtrate was passed through a macroporous adsorption resin column, followed by gradient elution with 20%, 40%, 60%, 80% and 90% (volume ratio) ethanol, and collected in 500 ml portions. The eluent was analyzed by silica gel H thin-layer chromatography, the developing solvent was "n-butanol-ethyl acetate-water" 5:0.5:4 (upper layer), and the color was developed by a 10% (volume ratio) sulfuric acid ethanol solution. Combine the same components of the chromatographic spots and recover the solvent under reduced pressure. Then apply the chromatography silica gel column, and eluted with the solvents of "chloroform-...

Embodiment 2

[0031] The extraction of the components is the same as in Example 1.

[0032] Weigh the following components (same as above): ginsenoside Rg1 30g, ginsenoside Rb1 28.5g, ginsenoside Re3.0g, ginsenoside Rd 7.5g and notoginsenoside R1 7.8g.

[0033] The preparation method is as follows: mix the above-mentioned components, dissolve in an appropriate amount with water for injection, add needles to decolorize with activated carbon, filter, add water for injection to the total amount, adjust pH to 6.7, filter, freeze-dry, and get ready.

Embodiment 3

[0035] Weigh the following components: ginsenoside Rg1 45g, ginsenoside Rb1 29g, and ginsenoside Re 2.5g.

[0036] The preparation method is as follows: mix the above-mentioned components, dissolve in proper amount with water for injection, add needle to decolor with activated carbon, filter, add water for injection to the total amount, adjust pH to 6.0, filter, freeze-dry, and get ready.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition and a preparation method thereof. The pharmaceutical composition contains ginsenoside Rg1, ginsenoside Rb1 and ginsenoside Re, wherein the weight ratio of ginsenoside Rg1: ginsenoside Rb1: ginsenoside Re is 1:0.7:1.2. The composition provided by the invention has notable effects and high safety, can alleviate apoplexy symptoms, obviously shortens the course of disease, improves depression of patients with apoplexy sequelae, and the like.

Description

Technical field [0001] The present invention relates to the field of medicine, in particular to a medicinal composition for treating hemorrhagic stroke or schizophrenia residual period. Background technique [0002] Stroke is a group of diseases whose main clinical manifestations are cerebral ischemia and hemorrhagic injury. It is also known as stroke or cerebrovascular accident. Stroke is a rapid onset, with a very high mortality and disability rate. According to a report by the World Health Organization, deaths due to stroke are the second highest death rate in the world, second only to cancer, and about 1 in the number of deaths per year. 4 people died of a stroke. There are more than 10 types of cancer. If the mortality rate of a single type is considered, stroke can be ranked first. In the United States, the mortality rate of first stroke patients is about 7%, and the mortality rate in my country is even higher. [0003] Stroke is also the primary cause of adult disability....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P9/10A61P25/18
Inventor 方同华
Owner HEILONGJIANG ZBD PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com